Table 3.

Cox regression analyses of HDL parameters as predictors of 1-year mortality in AHF patients.

		Univariable			Adjusted *
	SD	HR (95% CI) per 1 SD	p-Value	Events/n	HR (95% CI) per 1 SD	p-Value	Events/n
HDL-apoA-II	6.2	0.50 (0.41–0.62)	<0.001	117/314	0.67 (0.47–0.94)	0.020	111/302
HDL1-apoA-II	1.5	1.05 (0.89–1.25)	0.559	117/314	1.06 (0.85–1.32)	0.600	111/302
HDL2-apoA-II	0.9	0.73 (0.60–0.89)	0.002	117/314	0.72 (0.54–0.95)	0.019	111/302
HDL3-apoA-II	1.6	0.51 (0.40–0.63)	<0.001	117/314	0.59 (0.43–0.80)	<0.001	111/302
HDL4-apoA-II	5.0	0.51 (0.42–0.63)	<0.001	117/314	0.81 (0.60–1.10)	0.185	111/302
HDL-apoA-I	29.4	0.66 (0.54–0.80)	<0.001	117/314	1.00 (0.76–1.33)	0.980	111/302
HDL1-apoA-I	16.4	1.12 (0.95–1.32)	0.172	117/314	1.13 (0.92–1.39)	0.241	111/302
HDL2-apoA-I	4.6	0.77 (0.63–0.94)	0.011	117/314	0.98 (0.77–1.24)	0.839	111/302
HDL3-apoA-I	6.1	0.56 (0.46–0.69)	<0.001	117/314	0.79 (0.60–1.04)	0.096	111/302
HDL4-apoA-I	16.5	0.53 (0.43–0.65)	<0.001	117/314	0.92 (0.67–1.28)	0.632	111/302
HDL-p	8.3	0.53 (0.43–0.65)	<0.001	118/314	0.77 (0.55–1.07)	0.114	112/302
LHDL-p	3.3	0.98 (0.81–1.19)	0.836	100/268	1.17 (0.94–1.46)	0.150	97/262
SHDL-p	7.4	0.56 (0.44–0.70)	<0.001	101/290	0.85 (0.62–1.18)	0.330	97/280

Parameters significantly associated with 1-year mortality after adjustment as well as significant p-values (<0.05) are depicted in bold. Total and subfractions of HDL-apoA-II and HDL-apoA-I are given in mg/dL and HDL-p, LHDL-p, and SHDL-p in µmol/L. * Adjusted for age, sex, BMI, MAP, eGFR, BUN, CRP, NT-proBNP, hemoglobin, ALT, albumin, and total cholesterol. ALT, alanine aminotransferase; apoA-I, apolipoprotein A-I; apoA-II, apolipoprotein A-II; BMI, body mass index; BUN, blood urea nitrogen; C, cholesterol; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL-p, high-density lipoprotein particle concentration; L, large; MAP, mean arterial pressure; n, number of observations; NT-proBNP, N-terminal pro-brain natriuretic peptide; p, particle; S, small; SD, standard deviation.